Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis

Arthritis Care and Research

Volumn 67, Issue 6, 2015, Pages 842-847

  Haddad, Amir ^a   Thavaneswaran, Arane ^a   Ruiz Arruza, Ioana ^a   Pellett, Fawnda ^a   Chandran, Vinod ^a   Cook, Richard J ^b   Gladman, Dafna D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL DISEASE ACTIVITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PSORIATIC ARTHRITIS; REMISSION; SEX DIFFERENCE; SURVIVAL TIME; ADOLESCENT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; DRUG ADMINISTRATION; IMMUNOLOGY; MIDDLE AGED; RECURRENT DISEASE; REPRODUCIBILITY; RISK; RISK FACTOR; TIME; TREATMENT OUTCOME; VALIDATION STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; BLOOD SEDIMENTATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RECURRENCE; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84929934528     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22529     Document Type: Article

References (34)

1. Chandran V, Raychaudhuri SP., Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010; 34: 314-21.
2. Ibrahim G, Waxman R, Helliwell PS., The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009; 61: 1373-8.
3. McHugh NJ, Balachrishnan C, Jones SM., Progression of peripheral joint disease in psoriatic arthritis: a 5-year prospective study. Rheumatology (Oxford) 2003; 43: 778-83.
4. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML., Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809-12.
5. Kane D, Stafford L, Bresnihan B, FitzGerald O., A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003; 42: 1460-8.
6. Gladman DD., Disability and quality of life considerations: psoriatic arthritis. In:, Gordon GB, Ruderman E, editors. Psoriasis and psoriatic arthritis: an integral approach. Heidelberg: Springer-Verlag; 2005. p. 118-23.
7. Gladman DD, Farewell VT, Wong K, Husted J., Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998; 41: 1103-10.
8. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al., Adalimumab for long-term treatment of psoriatic arthritis: forty-eight-week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Arthritis Rheum 2007; 56: 476-88.
9. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al., Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-72.
10. Van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, et al., Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the Induction and Maintenance Psoriatic Arthritis Clinical Trial 2. Arthritis Rheum 2007; 56: 2698-707.
11. Kavanaugh A, Ritchlin C, and the GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006; 33: 1417-21.
12. Kavanaugh A, Fransen J., Defining remission in psoriatic arthritis. Clin Exp Rheumatol 2006; 24 Suppl 43: S83-7.
13. Coates LC, Fransen J, Helliwell PS., Defining disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010; 69: 48-53.
14. Coates L, Helliwell P., Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010; 62; 965-9.
15. Coates LC, Cook R, Lee K, Chandran V, Gladman DD., Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 2010; 62: 970-6.
16. Iervolino S, Di Minno MN, Peluso R, Lofrano M, Russolillo A, Di Minno G, et al., Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis-α blockers. J Rheumatol 2012; 39: 568-73.
17. Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CA, et al., Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010; 12: R94.
18. Eder L, Chandran V, Schentag CT, Shen H, Cook RJ, Gladman DD., Time and predictors of response to tumor necrosis factor-α blockers in psoriatic arthritis: an analysis of a longitudinal observation cohort. Rheumatology (Oxford) 2010; 49: 1361-6.
19. Taylor WJ, Gladman DD, Helliwell PS, Marchesoni A, Mease P, Mielants H., Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
20. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, et al., International spondyloarthritis interobserver reliability exercise: the INSPIRE study. II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007; 34: 1740-5.
21. Healy PJ, Helliwell PS., Measuring dactylitis in clinical trials: which is the best instrument to use? J Rheumatol 2007; 34: 1302-6.
22. Chandran V, Gottlieb A, Cook RJ, Duffin KC, Garg A, Helliwell P, et al., International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum 2009; 61: 1235-42.
23. Blackmore M, Gladman DD, Husted J, Long J, Farewell VT., Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995; 22: 886-93.
24. Husted J, Gladman DD, Long JA, Farewell VT, Cook R., Validating the SF-36 health questionnaire in patients with psoriatic arthritis. J Rheumatol 1997; 24: 511-7.
25. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G, Salonen D., Radiological assessment in psoriatic arthritis. Brit J Rheumatol 1998; 37: 760-5.
26. Begovich AB, Erlich HA., HLA typing for bone marrow transplantation: new polymerase chain reaction-based methods. JAMA 1995; 273: 586-91.
27. SAS Institute Inc. Chapter 10: the MIANALYZE procedure, version 8. 1999. URL: http://www.ats.ucla.edu/stat/sas/v8/mianalyzev802.pdf.
28. Berflund A,. An overview of survival analysis using complex sample data. 2011. URL: http://support.sas.com/resources/papers/proceedings11/338-2011.pdf.
29. Mease PJ, Heckaman M, Kary S, Kupper H., Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol 2013; 40: 647-52.
30. Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, FitzGerald O, et al., Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007; 34: 1167-70.
31. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Krueger GG, Callis-Duffin K, et al., The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013; 72: 986-91.
32. Gratacos J, Casado E, Real J, Torre-Alonso JC., Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 2007; 66: 493-7.
33. Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N, et al., Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 2013; 52: 62-7.
34. Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD,. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 2015; 74: 813-7.